Logo image of SCTL

SOCIETAL CDMO INC (SCTL) Stock Fundamental Analysis

NASDAQ:SCTL - Nasdaq - US75629F1093 - Common Stock - Currency: USD

1.1  +0.01 (+0.92%)

After market: 1.09 -0.01 (-0.91%)

Fundamental Rating

2

Overall SCTL gets a fundamental rating of 2 out of 10. We evaluated SCTL against 195 industry peers in the Pharmaceuticals industry. SCTL has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SCTL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SCTL has reported negative net income.
SCTL had a negative operating cash flow in the past year.
In the past 5 years SCTL always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SCTL reported negative operating cash flow in multiple years.
SCTL Yearly Net Income VS EBIT VS OCF VS FCFSCTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

SCTL's Return On Assets of -8.64% is fine compared to the rest of the industry. SCTL outperforms 74.37% of its industry peers.
The Return On Equity of SCTL (-22.61%) is better than 72.86% of its industry peers.
Industry RankSector Rank
ROA -8.64%
ROE -22.61%
ROIC N/A
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCTL Yearly ROA, ROE, ROICSCTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

SCTL's Gross Margin of 19.17% is in line compared to the rest of the industry. SCTL outperforms 49.75% of its industry peers.
In the last couple of years the Gross Margin of SCTL has declined.
The Profit Margin and Operating Margin are not available for SCTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
SCTL Yearly Profit, Operating, Gross MarginsSCTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

SCTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCTL has more shares outstanding
SCTL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCTL has been reduced compared to a year ago.
SCTL Yearly Shares OutstandingSCTL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
SCTL Yearly Total Debt VS Total AssetsSCTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.24, we must say that SCTL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SCTL (-1.24) is comparable to the rest of the industry.
SCTL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
SCTL's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. SCTL outperforms 55.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.24
ROIC/WACCN/A
WACC11.28%
SCTL Yearly LT Debt VS Equity VS FCFSCTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.07 indicates that SCTL should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.07, SCTL is doing worse than 85.93% of the companies in the same industry.
SCTL has a Quick Ratio of 1.07. This is a bad value and indicates that SCTL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SCTL (0.86) is worse than 83.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.86
SCTL Yearly Current Assets VS Current LiabilitesSCTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

SCTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.74%, which is quite impressive.
SCTL shows a small growth in Revenue. In the last year, the Revenue has grown by 4.91%.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%

3.2 Future

SCTL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.13% yearly.
The Revenue is expected to grow by 9.11% on average over the next years. This is quite good.
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SCTL Yearly Revenue VS EstimatesSCTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
SCTL Yearly EPS VS EstimatesSCTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCTL. In the last year negative earnings were reported.
Also next year SCTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCTL Price Earnings VS Forward Price EarningsSCTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

78.89% of the companies in the same industry are more expensive than SCTL, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.26
SCTL Per share dataSCTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

SCTL's earnings are expected to grow with 31.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y31.13%

More info and screens

0

5. Dividend

5.1 Amount

SCTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOCIETAL CDMO INC

NASDAQ:SCTL (4/5/2024, 8:19:35 PM)

After market: 1.09 -0.01 (-0.91%)

1.1

+0.01 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-22 2024-03-22/amc
Earnings (Next)05-08 2024-05-08/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner Change0%
Market Cap116.26M
Analysts78
Price Target1.12 (1.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.57%
Min EPS beat(2)-145.1%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-44.61%
Min EPS beat(4)-145.1%
Max EPS beat(4)1.96%
EPS beat(8)5
Avg EPS beat(8)-15.62%
EPS beat(12)9
Avg EPS beat(12)5.08%
EPS beat(16)10
Avg EPS beat(16)-57.49%
Revenue beat(2)1
Avg Revenue beat(2)0.76%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)6.12%
Revenue beat(4)2
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-4.6%
Max Revenue beat(4)6.12%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)7
Avg Revenue beat(12)1.72%
Revenue beat(16)9
Avg Revenue beat(16)-0.52%
PT rev (1m)-47.2%
PT rev (3m)-47.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.98
P/tB 7.58
EV/EBITDA 27.26
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.9
BVpS0.56
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.64%
ROE -22.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.17%
FCFM N/A
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.06
Cap/Depr 92.47%
Cap/Sales 8.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 0.86
Altman-Z -1.24
F-Score4
WACC11.28%
ROIC/WACCN/A
Cap/Depr(3y)87.57%
Cap/Depr(5y)90.2%
Cap/Sales(3y)8.33%
Cap/Sales(5y)8.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%
EBIT growth 1Y-1334.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year472.86%
EBIT Next 3Y112.66%
EBIT Next 5YN/A
FCF growth 1Y22.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.39%
OCF growth 3YN/A
OCF growth 5YN/A